Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Stenosing Tenosynovitis
Interventions: Amniotic fluid injection, Steroid injection; Biological
Lead sponsor: J&M Shuler; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Heart Failure
Interventions: sc2Wear Furosemide Infusor; Combination Product
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Brighton, Massachusetts

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo, mRNA-1273.222; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 4,328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 48
States / cities: Banning, California • La Mesa, California • Lake Worth, Florida + 41 more

Conditions: Opioid Use
Interventions: Information Sheet, Deterra Drug Deactivation System; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Age Related Macular Degeneration
Interventions: Ranibizumab; Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19 Pneumonia, Impaired Respiratory Function
Interventions: MAS825, Placebo, Standard of Care (SoC); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Chula Vista, California • Glendale, California • Irvine, California + 17 more

Conditions: Non Cystic Fibrosis Bronchiectasis
Interventions: Ciprofloxacin dispersion for inhalation, Placebo; Drug
Lead sponsor: Aradigm Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more

Conditions: Heart Failure, ADHF, Acute MI
Interventions: COMPASSION Digital Biomarker; Other
Lead sponsor: Aventyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Opioid Use, Kidney Diseases, Pain, Postoperative, Postoperative Complications, Postoperative Nausea and Vomiting
Interventions: multimodal pain management, goal directed fluid management, preoperative carbohydrate loading, Donor nephrectomy, regional anesthesia; Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dyspnea, Acute Heart Failure Syndrome, Pulmonary Congestion
Interventions: IMED-4; Device
Lead sponsor: Intersection Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • Detroit, Michigan • Columbus, Ohio

Conditions: Demoralization
Interventions: Psilocybin, Ketamine; Drug
Lead sponsor: Charles S. Grob, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Greenbrae, California • Los Angeles, California • San Francisco, California + 2 more

Conditions: Acute Kidney Injury
Interventions: Furosemide, Peritoneal Dialysis; Drug · Procedure
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 6 Months
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Ciliary Dyskinesia, PCD
Interventions: Exercise, HS pretreatment with Exercise; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Polycystic Ovary Syndrome, Normal Volunteers
Interventions: IVF Antagonist Protocol; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors
Interventions: KB-GDT-01; Biological
Lead sponsor: Kiromic BioPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Tucson, Arizona • Beverly Hills, California • Pittsburgh, Pennsylvania + 2 more

Conditions: Encephalitis
Interventions: MVA-BN-WEV, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Sacramento, California • Lilburn, Georgia • Lenexa, Kansas + 6 more

Conditions: Tumor Surgery
Interventions: Caloric Restriction Diet; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions: XEN496; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 1 Month to 6 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Tacoma, Washington

Conditions: Heart Failure
Interventions: Impedance Monitoring Feature; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more

Conditions: Idiopathic Edema Nocturia
Interventions: Not listed
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions: Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 21 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • New York, New York • Cincinnati, Ohio

Conditions: Sepsis
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Beta-thalassemia, Iron Overload
Interventions: Deferasirox; Drug
Lead sponsor: Novartis; Industry
Eligibility: 10 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois

Conditions: Healthy
Interventions: BT-600, BT-600 Placebo; Combination Product
Lead sponsor: Biora Therapeutics, Inc.; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Corticosteroid vs. Amniotic Fluid Injections in Patients With Trigger Finger

Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Pain and Medication Use Following Surgery

A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions

Enhanced Recovery After Surgery in Kidney Transplant Donors

Precision of IMED-4 Lung Fluid Measurements

Pragmatic Trial of Psilocybin Therapy in Palliative Care

Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass

Clearance in Primary Ciliary Dyskinesia

Proteomics & Glyco-Proteomic Analysis of Follicular Fluid

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Detect Fluid Early From Intra-thoracic Impedance Monitoring

Study of Idiopathic Edema

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

A Simple Clinical Tool to Help Assess Patient Volume (Fluid) Status

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects